Evidence map›Paper›PMID 33283602›Full record

ReviewJournal of the renin-angiotensin-aldosterone system : JRAAS

Angiotensin-converting enzyme 2, the complement system, the kallikrein-kinin system, type-2 diabetes, interleukin-6, and their interactions regarding the complex COVID-19 pathophysiological crossroads.

Martijn Hoevenaar, Dolf Goossens, Janne Roorda

Abstract readReview
In one paragraph

Review in Journal of the renin-angiotensin-aldosterone system : JRAAS. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Martijn HoevenaarIndependent Researcher, Breda, The Netherlands.ORCID https://orcid.org/0000-0003-1906-703X
Dolf GoossensIndependent Researcher, Breda, The Netherlands.ORCID https://orcid.org/0000-0003-0417-991X
Janne RoordaMedical Doctor, General Practice van Dijk, Oisterwijk, The Netherlands.ORCID https://orcid.org/0000-0002-6624-6666

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Because of the current COVID-19-pandemic, the world is currently being held hostage in various lockdowns. ACE2 facilitates SARS-CoV-2 cell-entry, and is at the very center of several pathophysiological pathways regarding the RAAS, CS, KKS, T2DM, and IL-6. Their interactions with severe COVID-19 complications (e.g. ARDS and thrombosis), and potential therapeutic targets for pharmacological intervention, will be reviewed.

Indexed as

Kallikrein-Kinin SystemAngiotensin-Converting Enzyme 2Complement System ProteinsCOVID-19COVID-19 Drug TreatmentDiabetes Mellitus, Type 2HumansInterleukin-6SARS-CoV-2Angiotensin-Converting Enzyme 2Complement System ProteinsInterleukin-6angiotensin-converting enzyme 2complementCOVID-19diabetesinterleukin-6kallikrein-kinin systemrenin angiotensin aldosterone systemthrombosis

Identifiers

PMID33283602
PMCPMC7724427

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.